Pen-injector is a pre-filled disposable syringe-pen for multiple injections containing a hypoglycemic agent, an analogue of glucagon-like peptide-1 (GLP-1) — Semaglutide.
Semaglutide 4mg pen (0.25 mg/dose, 0.5 mg/dose, 1.0 mg/dose) — a solution for subcutaneous administration in a pre-filled syringe-pen allows for the administration of doses of 0.25 mg, 0.5 mg and 1.0 mg. Syringe-pen is designed to titrate a dose of 0.25 mg and maintain a therapeutic dose of 0.5 mg and 1.0 mg.
Semaglutide 6.8mg pen (1.7 mg/dose) — a solution for subcutaneous administration in a pre-filled syringe-pen allows for the administration of dose only 1.7mg.
Semaglutide 9.6mg pen (2.4 mg/dose) — a solution for subcutaneous administration in a pre-filled syringe-pen allows for the administration of dose only 2.4mg.
Semaglutide is an analogue of glucagon-like peptide 1, which is produced in the human body and acts on receptors that control appetite and satiety, and also regulates insulin secretion.
Health benefits of semaglutide:
- Semaglutide suppresses appetite and reduces calorie consumption by 18-35% during the day
- Semaglutide reduces body weight primarily by reducing fat mass
- Semaglutide reduces the risk of serious cardiovascular events
- Semaglutide reduces triglyceride and cholesterol levels
- Semaglutide reduces systolic blood pressure
- Semaglutide reduces blood glucose levels in adults with type 2 diabetes (plasma glucose and glycated hemoglobin (HbA1c))
